Rinri Therapeutics is developing engineered stem cell therapies specifically for the regeneration of auditory tissues affected by sensorineural hearing loss. This approach aims to restore hearing functionality and improve patient quality of life by addressing the underlying cellular damage caused by various auditory conditions.
Funding
$21.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
IUFounders
Product
Problem
Sensorineural hearing loss, resulting from damage to auditory tissues, can significantly impair hearing functionality and diminish the quality of life for affected individuals. Current treatments often fail to address the underlying cellular damage, offering limited regenerative potential.
Solution
Rinri Therapeutics is pioneering the development of regenerative cell therapies designed to restore auditory function in individuals with sensorineural hearing loss. Their approach involves engineering stem cells to regenerate damaged auditory tissues, aiming to address the root cause of hearing loss rather than merely managing symptoms. By focusing on cellular repair and regeneration, Rinri Therapeutics seeks to provide long-term improvements in hearing and overall patient well-being. The company is currently in the clinical stage, advancing its portfolio of first-in-class hearing restoration products.
Target Audience
The primary target audience includes individuals suffering from sensorineural hearing loss and clinicians specializing in audiology and hearing restoration.
Features
- Engineered stem cell therapies for regeneration of auditory tissues
- Focus on addressing the underlying cellular damage in sensorineural hearing loss
- Portfolio of first-in-class approaches to hearing restoration
- Clinical-stage development